{"title": "Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/personalized_medicine.xml", "value": "Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2019/02/190227170246.htm"}], "link": "https://www.sciencedaily.com/releases/2019/02/190227170246.htm", "summary": "Researchers have revealed that a liquid biopsy test called Guardant360\u00ae, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/personalized_medicine.xml", "value": "Researchers have revealed that a liquid biopsy test called Guardant360\u00ae, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy."}, "published": "Wed, 27 Feb 2019 17:02:46 EST", "published_parsed": [2019, 2, 27, 22, 2, 46, 2, 58, 0], "id": "https://www.sciencedaily.com/releases/2019/02/190227170246.htm", "guidislink": false}